Skip to main content
Top
Published in: Sleep and Breathing 4/2010

01-12-2010 | Review

Hypoxia—implications for pharmaceutical developments

Authors: Lucas Donovan, Scott M. Welford, John Haaga, Joseph LaManna, Kingman P. Strohl

Published in: Sleep and Breathing | Issue 4/2010

Login to get access

Abstract

Cells sense oxygen availability using not only the absolute value for cellular oxygen in regard to its energetic and metabolic functions, but also the gradient from the cell surface to the lowest levels in the mitochondria. Signals are used for regulatory purposes locally as well as in the generation of cellular, tissue, and humoral remodeling. Lowered oxygen availability (hypoxia) is theoretically important in the consideration of pharmacology because (1) hypoxia can alter cellular function and thereby the therapeutic effectiveness of the agent, (2) therapeutic agents may potentiate or protect against hypoxia-induced pathology, (3) hypoxic conditions may potentiate or mitigate drug-induced toxicity, (4) hypoxia may alter drug metabolism and thereby therapeutic effectiveness, and (5) therapeutic agents might alter the relative coupling of blood flow and energy metabolism in an organ. The prototypic biochemical effect of hypoxia is related to its known role as a cofactor in a number of enzymatic reactions, e.g., oxidases and oxygenases, which are affected independently from the bioenergetic effect of low oxygen on energetic functions. The cytochrome P-450 family of enzymes is another example. Here, there is a direct effect of oxygen availability on the conformation of the enzyme, thereby altering the metabolism of drug substrates. Indirectly, the NADH/NAD+ ratio is increased with 10% inspired oxygen, leading not only to reduced oxidation of ethanol but also to reduction of azo- and nitro-compounds to amines and disulfides to sulfhydryls. With chronic hypoxia, many of these processes are reversed, suggesting that hypoxia induces the drug-metabolizing systems. Support for this comes from observations that hypoxia can induce the hypoxic inducible factors which in turn alters transcription and function of some but not all cytochrome P-450 isoforms. Hypoxia is identified as a cofactor in cancer expression and metastatic potential. Thus, the effects of hypoxia play an important role in pharmacology, and the signaling pathways that are affected by hypoxia could become new targets for novel therapy or avenues for prevention.
Literature
1.
go back to reference Koch LG, Britton SL (2008) Aerobic metabolism underlies complexity and capacity. J Physiol 586:83–95CrossRefPubMed Koch LG, Britton SL (2008) Aerobic metabolism underlies complexity and capacity. J Physiol 586:83–95CrossRefPubMed
2.
go back to reference Britton SL, Koch LG (2005) Animal models of complex diseases: an initial strategy. IUBMB Life 57:631–638CrossRefPubMed Britton SL, Koch LG (2005) Animal models of complex diseases: an initial strategy. IUBMB Life 57:631–638CrossRefPubMed
3.
go back to reference Budd GE (2008) The earliest fossil record of the animals and its significance. Philos Trans R Soc Lond B Biol Sci 363:1425–1434CrossRefPubMed Budd GE (2008) The earliest fossil record of the animals and its significance. Philos Trans R Soc Lond B Biol Sci 363:1425–1434CrossRefPubMed
4.
go back to reference Hochachka PW, Land SC, Buck LT (1997) Oxygen sensing and signal transduction in metabolic defense against hypoxia: lessons from vertebrate facultative anaerobes. Comp Biochem Physiol A Physiol 118:23–29CrossRefPubMed Hochachka PW, Land SC, Buck LT (1997) Oxygen sensing and signal transduction in metabolic defense against hypoxia: lessons from vertebrate facultative anaerobes. Comp Biochem Physiol A Physiol 118:23–29CrossRefPubMed
5.
go back to reference Webster WS, Abela D (2007) The effect of hypoxia in development. Birth Defects Res C Embryo Today 81:215–228CrossRefPubMed Webster WS, Abela D (2007) The effect of hypoxia in development. Birth Defects Res C Embryo Today 81:215–228CrossRefPubMed
6.
go back to reference Koch LG, Britton SL (2007) Evolution, atmospheric oxygen, and complex disease. Physiol Genomics 30:205–208CrossRefPubMed Koch LG, Britton SL (2007) Evolution, atmospheric oxygen, and complex disease. Physiol Genomics 30:205–208CrossRefPubMed
7.
go back to reference Hochachka PW (1998) Mechanisms and evolution of hypoxia-tolerance in humans. J Exp Biol 201:1243–1254PubMed Hochachka PW (1998) Mechanisms and evolution of hypoxia-tolerance in humans. J Exp Biol 201:1243–1254PubMed
9.
10.
go back to reference Dowling DK, Simmons LW (2009) Reactive oxygen species as universal constraints in life-history evolution. Proc Biol Sci 276:1737–1745CrossRefPubMed Dowling DK, Simmons LW (2009) Reactive oxygen species as universal constraints in life-history evolution. Proc Biol Sci 276:1737–1745CrossRefPubMed
11.
go back to reference Beilman GJ, Cerra FB (1996) The future. Monitoring cellular energetics. Crit Care Clin 12:1031–1042CrossRefPubMed Beilman GJ, Cerra FB (1996) The future. Monitoring cellular energetics. Crit Care Clin 12:1031–1042CrossRefPubMed
13.
go back to reference Caille V, Squara P (2006) Oxygen uptake-to-delivery relationship: a way to assess adequate flow. Crit Care 10(Suppl 3):4CrossRef Caille V, Squara P (2006) Oxygen uptake-to-delivery relationship: a way to assess adequate flow. Crit Care 10(Suppl 3):4CrossRef
14.
go back to reference Levy RJ, Deutschman CS (2007) Cytochrome c oxidase dysfunction in sepsis. Crit Care Med 35:S468–475CrossRefPubMed Levy RJ, Deutschman CS (2007) Cytochrome c oxidase dysfunction in sepsis. Crit Care Med 35:S468–475CrossRefPubMed
15.
go back to reference Kunze K (1969) Significance of oxygen pressure field measurements in human muscle, with special reference on PO2 micro-needle electrodes. Progr Respir Res 3:153–157 Kunze K (1969) Significance of oxygen pressure field measurements in human muscle, with special reference on PO2 micro-needle electrodes. Progr Respir Res 3:153–157
16.
go back to reference Van Den Brenk HA, Jamieson D (1962) Potentiation by anaesthetics of brain damage due to breathing high-pressure oxygen in mammals. Nature 194:777–778CrossRef Van Den Brenk HA, Jamieson D (1962) Potentiation by anaesthetics of brain damage due to breathing high-pressure oxygen in mammals. Nature 194:777–778CrossRef
17.
go back to reference Gnaiger E, Lassnig B, Kuznetsov A, Rieger G, Margreiter R (1998) Mitochondrial oxygen affinity, respiratory flux control and excess capacity of cytochrome c oxidase. J Exp Biol 201:1129–1139PubMed Gnaiger E, Lassnig B, Kuznetsov A, Rieger G, Margreiter R (1998) Mitochondrial oxygen affinity, respiratory flux control and excess capacity of cytochrome c oxidase. J Exp Biol 201:1129–1139PubMed
18.
go back to reference Gnaiger E, Steinlechner-Maran R, Mendez G, Eberl T, Margreiter R (1995) Control of mitochondrial and cellular respiration by oxygen. J Bioenerg Biomembr 27:583–596CrossRefPubMed Gnaiger E, Steinlechner-Maran R, Mendez G, Eberl T, Margreiter R (1995) Control of mitochondrial and cellular respiration by oxygen. J Bioenerg Biomembr 27:583–596CrossRefPubMed
19.
go back to reference Garofalo F, Pellegrino D, Amelio D, Tota B (2009) The Antarctic hemoglobinless icefish, fifty five years later: a unique cardiocirculatory interplay of disaptation and phenotypic plasticity. Comp Biochem Physiol A Mol Integr Physiol 154:10–28CrossRefPubMed Garofalo F, Pellegrino D, Amelio D, Tota B (2009) The Antarctic hemoglobinless icefish, fifty five years later: a unique cardiocirculatory interplay of disaptation and phenotypic plasticity. Comp Biochem Physiol A Mol Integr Physiol 154:10–28CrossRefPubMed
20.
go back to reference Gonzalez NC, Howlett RA, Henderson KK, Koch LG, Britton SL, Wagner HE, Favret F, Wagner PD (2006) Systemic oxygen transport in rats artificially selected for running endurance. Respir Physiol Neurobiol 151:141–150CrossRefPubMed Gonzalez NC, Howlett RA, Henderson KK, Koch LG, Britton SL, Wagner HE, Favret F, Wagner PD (2006) Systemic oxygen transport in rats artificially selected for running endurance. Respir Physiol Neurobiol 151:141–150CrossRefPubMed
21.
go back to reference Zuurbier CJ, van Iterson M, Ince C (1999) Functional heterogeneity of oxygen supply-consumption ratio in the heart. Cardiovasc Res 44:488–497CrossRefPubMed Zuurbier CJ, van Iterson M, Ince C (1999) Functional heterogeneity of oxygen supply-consumption ratio in the heart. Cardiovasc Res 44:488–497CrossRefPubMed
22.
go back to reference Prabhakar NR (2006) O2 sensing at the mammalian carotid body: why multiple O2 sensors and multiple transmitters? Exp Physiol 91:17–23CrossRefPubMed Prabhakar NR (2006) O2 sensing at the mammalian carotid body: why multiple O2 sensors and multiple transmitters? Exp Physiol 91:17–23CrossRefPubMed
23.
go back to reference Liss B, Roeper J (2001) Molecular physiology of neuronal K-ATP channels (review). Mol Membr Biol 18:117–127CrossRefPubMed Liss B, Roeper J (2001) Molecular physiology of neuronal K-ATP channels (review). Mol Membr Biol 18:117–127CrossRefPubMed
24.
go back to reference Taburet AM, Tollier C, Richard C (1990) The effect of respiratory disorders on clinical pharmacokinetic variables. Clin Pharmacokinet 19:462–490CrossRefPubMed Taburet AM, Tollier C, Richard C (1990) The effect of respiratory disorders on clinical pharmacokinetic variables. Clin Pharmacokinet 19:462–490CrossRefPubMed
25.
go back to reference Richer M, Lam YW (1993) Hypoxia, arterial pH and theophylline disposition. Clin Pharmacokinet 25:283–299CrossRefPubMed Richer M, Lam YW (1993) Hypoxia, arterial pH and theophylline disposition. Clin Pharmacokinet 25:283–299CrossRefPubMed
26.
go back to reference Burke PV, Poyton RO (1998) Structure/function of oxygen-regulated isoforms in cytochrome c oxidase. J Exp Biol 201:1163–1175PubMed Burke PV, Poyton RO (1998) Structure/function of oxygen-regulated isoforms in cytochrome c oxidase. J Exp Biol 201:1163–1175PubMed
27.
go back to reference Lahiri S, Antosiewicz J, Pokorski M (2007) A common oxygen sensor regulates the sensory discharge and glomus cell HIF-1alpha in the rat carotid body. J Physiol Pharmacol 58(Suppl 5):327–333PubMed Lahiri S, Antosiewicz J, Pokorski M (2007) A common oxygen sensor regulates the sensory discharge and glomus cell HIF-1alpha in the rat carotid body. J Physiol Pharmacol 58(Suppl 5):327–333PubMed
28.
go back to reference Acker T, Acker H (2004) Cellular oxygen sensing need in CNS function: physiological and pathological implications. J Exp Biol 207:3171–3188CrossRefPubMed Acker T, Acker H (2004) Cellular oxygen sensing need in CNS function: physiological and pathological implications. J Exp Biol 207:3171–3188CrossRefPubMed
29.
go back to reference Mironov V, Hritz MA, LaManna JC, Hudetz AG, Harik SI (1994) Architectural alterations in rat cerebral microvessels after hypobaric hypoxia. Brain Res 660:73–80CrossRefPubMed Mironov V, Hritz MA, LaManna JC, Hudetz AG, Harik SI (1994) Architectural alterations in rat cerebral microvessels after hypobaric hypoxia. Brain Res 660:73–80CrossRefPubMed
30.
go back to reference Lahiri S, Roy A, Li J, Baby SM, Mokashi A, Di Giulio C (2004) Role of Fe2+ in oxygen sensing in the carotid body. Adv Exp Med Biol 551:59–64CrossRefPubMed Lahiri S, Roy A, Li J, Baby SM, Mokashi A, Di Giulio C (2004) Role of Fe2+ in oxygen sensing in the carotid body. Adv Exp Med Biol 551:59–64CrossRefPubMed
31.
go back to reference Jamieson D, van den Brenk HA (1965) Electrode size and tissue pO2 measurement in rats exposed to air or high pressure oxygen. J Appl Physiol 20:514–518PubMed Jamieson D, van den Brenk HA (1965) Electrode size and tissue pO2 measurement in rats exposed to air or high pressure oxygen. J Appl Physiol 20:514–518PubMed
32.
go back to reference Cramer T, Yamanishi Y, Clausen BE, Forster I, Pawlinski R, Mackman N, Haase VH, Jaenisch R, Corr M, Nizet V, Firestein GS, Gerber HP, Ferrara N, Johnson RS (2003) HIF-1alpha is essential for myeloid cell-mediated inflammation. Cell 112:645–657CrossRefPubMed Cramer T, Yamanishi Y, Clausen BE, Forster I, Pawlinski R, Mackman N, Haase VH, Jaenisch R, Corr M, Nizet V, Firestein GS, Gerber HP, Ferrara N, Johnson RS (2003) HIF-1alpha is essential for myeloid cell-mediated inflammation. Cell 112:645–657CrossRefPubMed
33.
go back to reference Korzeniewski B (1998) Is it possible to predict any properties of oxidative phosphorylation in a theoretical way? Mol Cell Biochem 184:345–358CrossRefPubMed Korzeniewski B (1998) Is it possible to predict any properties of oxidative phosphorylation in a theoretical way? Mol Cell Biochem 184:345–358CrossRefPubMed
34.
go back to reference Keevil T, Mason HS (1978) Molecular oxygen in biological oxidations—an overview. Meth Enzymol 52:3–40CrossRefPubMed Keevil T, Mason HS (1978) Molecular oxygen in biological oxidations—an overview. Meth Enzymol 52:3–40CrossRefPubMed
35.
go back to reference Jones DP, Aw TY, Shan X (1989) Drug metabolism and toxicity during hypoxia. Drug Metab Rev 2–4:247–260CrossRef Jones DP, Aw TY, Shan X (1989) Drug metabolism and toxicity during hypoxia. Drug Metab Rev 2–4:247–260CrossRef
36.
go back to reference Feiters MC (2001) Mimicking biological electron transfer and oxygen activation involving iron and copper proteins: a bio(in)organic supramolecular approach. Met Ions Biol Syst 38:461–655PubMed Feiters MC (2001) Mimicking biological electron transfer and oxygen activation involving iron and copper proteins: a bio(in)organic supramolecular approach. Met Ions Biol Syst 38:461–655PubMed
37.
go back to reference Sun H, Scott DO (2010) Structure-based drug metabolism predictions for drug design. Chem Biol Drug Des 75:3–17CrossRefPubMed Sun H, Scott DO (2010) Structure-based drug metabolism predictions for drug design. Chem Biol Drug Des 75:3–17CrossRefPubMed
38.
go back to reference Schumacker PT, Chandel N, Agusti AG (1993) Oxygen conformance of cellular respiration in hepatocytes. Am J Physiol 265:L395–402PubMed Schumacker PT, Chandel N, Agusti AG (1993) Oxygen conformance of cellular respiration in hepatocytes. Am J Physiol 265:L395–402PubMed
39.
go back to reference Subramanian RM, Chandel N, Budinger GR, Schumacker PT (2007) Hypoxic conformance of metabolism in primary rat hepatocytes: a model of hepatic hibernation. Hepatology 45:455–464CrossRefPubMed Subramanian RM, Chandel N, Budinger GR, Schumacker PT (2007) Hypoxic conformance of metabolism in primary rat hepatocytes: a model of hepatic hibernation. Hepatology 45:455–464CrossRefPubMed
40.
go back to reference Heerlein K, Schulze A, Hotz L, Bartsch P, Mairbaurl H (2005) Hypoxia decreases cellular ATP demand and inhibits mitochondrial respiration of a549 cells. Am J Respir Cell Mol Biol 32:44–51CrossRefPubMed Heerlein K, Schulze A, Hotz L, Bartsch P, Mairbaurl H (2005) Hypoxia decreases cellular ATP demand and inhibits mitochondrial respiration of a549 cells. Am J Respir Cell Mol Biol 32:44–51CrossRefPubMed
41.
go back to reference Hsu T, Adereth Y, Kose N, Dammai V (2006) Endocytic function of von Hippel-Lindau tumor suppressor protein regulates surface localization of fibroblast growth factor receptor 1 and cell motility. J Biol Chem 281:12069–12080CrossRefPubMed Hsu T, Adereth Y, Kose N, Dammai V (2006) Endocytic function of von Hippel-Lindau tumor suppressor protein regulates surface localization of fibroblast growth factor receptor 1 and cell motility. J Biol Chem 281:12069–12080CrossRefPubMed
42.
go back to reference Wolin MS, Ahmad M, Gao Q, Gupte SA (2007) Cytosolic NAD(P)H regulation of redox signaling and vascular oxygen sensing. Antioxid Redox Signal 9:671–678CrossRefPubMed Wolin MS, Ahmad M, Gao Q, Gupte SA (2007) Cytosolic NAD(P)H regulation of redox signaling and vascular oxygen sensing. Antioxid Redox Signal 9:671–678CrossRefPubMed
43.
go back to reference Fradette C, Du Souich P (2004) Effect of hypoxia on cytochrome P450 activity and expression. Curr Drug Metab 5:257–271CrossRefPubMed Fradette C, Du Souich P (2004) Effect of hypoxia on cytochrome P450 activity and expression. Curr Drug Metab 5:257–271CrossRefPubMed
44.
go back to reference Savransky V, Reinke C, Jun J, Bevans-Fonti S, Nanayakkara A, Li J, Myers AC, Torbenson MS, Polotsky VY (2009) Chronic intermittent hypoxia and acetaminophen induce synergistic liver injury in mice. Exp Physiol 94:228–239CrossRefPubMed Savransky V, Reinke C, Jun J, Bevans-Fonti S, Nanayakkara A, Li J, Myers AC, Torbenson MS, Polotsky VY (2009) Chronic intermittent hypoxia and acetaminophen induce synergistic liver injury in mice. Exp Physiol 94:228–239CrossRefPubMed
45.
go back to reference Smith LL (1987) Mechanism of paraquat toxicity in lung and its relevance to treatment. Hum Toxicol 6:31–36CrossRefPubMed Smith LL (1987) Mechanism of paraquat toxicity in lung and its relevance to treatment. Hum Toxicol 6:31–36CrossRefPubMed
46.
go back to reference Demeere JL (1984) Paraquat toxicity. The use of hypoxic ventilation. Acta Anaesthesiol Belg 35:219–230PubMed Demeere JL (1984) Paraquat toxicity. The use of hypoxic ventilation. Acta Anaesthesiol Belg 35:219–230PubMed
47.
go back to reference Riepe MW, Esclaire F, Kasischke K, Schreiber S, Nakase H, Kempski O, Ludolph AC, Dirnagl U, Hugon J (1997) Increased hypoxic tolerance by chemical inhibition of oxidative phosphorylation: “chemical preconditioning”. J Cereb Blood Flow Metab 17:257–264CrossRefPubMed Riepe MW, Esclaire F, Kasischke K, Schreiber S, Nakase H, Kempski O, Ludolph AC, Dirnagl U, Hugon J (1997) Increased hypoxic tolerance by chemical inhibition of oxidative phosphorylation: “chemical preconditioning”. J Cereb Blood Flow Metab 17:257–264CrossRefPubMed
48.
go back to reference Huber R, Kasischke K, Ludolph AC, Riepe MW (1999) Increase of cellular hypoxic tolerance by erythromycin and other antibiotics. NeuroReport 10:1543–1546CrossRefPubMed Huber R, Kasischke K, Ludolph AC, Riepe MW (1999) Increase of cellular hypoxic tolerance by erythromycin and other antibiotics. NeuroReport 10:1543–1546CrossRefPubMed
49.
go back to reference Riepe MW, Kasischke K, Raupach A (1997) Acetylsalicylic acid increases tolerance against hypoxic and chemical hypoxia. Stroke 28:2006–2011PubMed Riepe MW, Kasischke K, Raupach A (1997) Acetylsalicylic acid increases tolerance against hypoxic and chemical hypoxia. Stroke 28:2006–2011PubMed
50.
go back to reference Burtscher M, Likar R, Nachbauer W, Philadelphy M (1998) Aspirin for prophylaxis against headache at high altitudes: randomised, double blind, placebo controlled trial. Bmj 316:1057–1058PubMed Burtscher M, Likar R, Nachbauer W, Philadelphy M (1998) Aspirin for prophylaxis against headache at high altitudes: randomised, double blind, placebo controlled trial. Bmj 316:1057–1058PubMed
51.
go back to reference LaManna JC, Chavez JC, Pichiule P (2004) Structural and functional adaptation to hypoxia in the rat brain. J Exp Biol 207:3163–3169CrossRefPubMed LaManna JC, Chavez JC, Pichiule P (2004) Structural and functional adaptation to hypoxia in the rat brain. J Exp Biol 207:3163–3169CrossRefPubMed
53.
go back to reference Fradette C, du Souich P (2003) Hypoxia-inducible factor-1 and activator protein-1 modulate the upregulation of CYP3A6 induced by hypoxia. Br J Pharmacol 140:1146–1154CrossRefPubMed Fradette C, du Souich P (2003) Hypoxia-inducible factor-1 and activator protein-1 modulate the upregulation of CYP3A6 induced by hypoxia. Br J Pharmacol 140:1146–1154CrossRefPubMed
54.
go back to reference Semenza GL (2007) Evaluation of HIF-1 inhibitors as anticancer agents. Drug Discov Today 12:853–859CrossRefPubMed Semenza GL (2007) Evaluation of HIF-1 inhibitors as anticancer agents. Drug Discov Today 12:853–859CrossRefPubMed
55.
go back to reference Semenza GL (2007) Oxygen-dependent regulation of mitochondrial respiration by hypoxia-inducible factor 1. Biochem J 405:1–9PubMed Semenza GL (2007) Oxygen-dependent regulation of mitochondrial respiration by hypoxia-inducible factor 1. Biochem J 405:1–9PubMed
56.
go back to reference Beauvoit B, Rigoulet M (2001) Regulation of cytochrome c oxidase by adenylic nucleotides. Is oxidative phosphorylation feedback regulated by its end-products? IUBMB Life 52:143–152CrossRefPubMed Beauvoit B, Rigoulet M (2001) Regulation of cytochrome c oxidase by adenylic nucleotides. Is oxidative phosphorylation feedback regulated by its end-products? IUBMB Life 52:143–152CrossRefPubMed
58.
go back to reference Tavani A, La Vecchia C (2004) Coffee, decaffeinated coffee, tea and cancer of the colon and rectum: a review of epidemiological studies, 1990-2003. Cancer Causes Control 15:743–757CrossRefPubMed Tavani A, La Vecchia C (2004) Coffee, decaffeinated coffee, tea and cancer of the colon and rectum: a review of epidemiological studies, 1990-2003. Cancer Causes Control 15:743–757CrossRefPubMed
59.
go back to reference LaCroix AZ, Mead LA, Liang KY, Thomas CB, Pearson TA (1986) Coffee consumption and the incidence of coronary heart disease. N Engl J Med 315:977–982CrossRefPubMed LaCroix AZ, Mead LA, Liang KY, Thomas CB, Pearson TA (1986) Coffee consumption and the incidence of coronary heart disease. N Engl J Med 315:977–982CrossRefPubMed
60.
go back to reference Merighi S, Benini A, Mirandola P, Gessi S, Varani K, Simioni C, Leung E, Maclennan S, Baraldi PG, Borea PA (2007) Caffeine inhibits adenosine-induced accumulation of hypoxia-inducible factor-1alpha, vascular endothelial growth factor, and interleukin-8 expression in hypoxic human colon cancer cells. Mol Pharmacol 72:395–406CrossRefPubMed Merighi S, Benini A, Mirandola P, Gessi S, Varani K, Simioni C, Leung E, Maclennan S, Baraldi PG, Borea PA (2007) Caffeine inhibits adenosine-induced accumulation of hypoxia-inducible factor-1alpha, vascular endothelial growth factor, and interleukin-8 expression in hypoxic human colon cancer cells. Mol Pharmacol 72:395–406CrossRefPubMed
61.
go back to reference Purushothaman J, Suryakumar G, Shukla D, Jayamurthy H, Kasiganesan H, Kumar R, Sawhney RC (2010) Modulation of hypoxia-induced pulmonary vascular leakage in rats by seabuckthorn (Hippophae rhamnoides L.). Evid Based Complement Alternat Med (in press) Purushothaman J, Suryakumar G, Shukla D, Jayamurthy H, Kasiganesan H, Kumar R, Sawhney RC (2010) Modulation of hypoxia-induced pulmonary vascular leakage in rats by seabuckthorn (Hippophae rhamnoides L.). Evid Based Complement Alternat Med (in press)
62.
go back to reference Brown JM, Wilson WR (2004) Exploiting tumour hypoxia in cancer treatment. Nat Rev Cancer 4:437–447CrossRefPubMed Brown JM, Wilson WR (2004) Exploiting tumour hypoxia in cancer treatment. Nat Rev Cancer 4:437–447CrossRefPubMed
63.
go back to reference Reynolds TY, Rockwell S, Glazer PM (1996) Genetic instability induced by the tumor microenvironment. Cancer Res 56:5754–5757PubMed Reynolds TY, Rockwell S, Glazer PM (1996) Genetic instability induced by the tumor microenvironment. Cancer Res 56:5754–5757PubMed
64.
go back to reference Chen Y, Cairns R, Papandreou I, Koong A, Denko NC (2009) Oxygen consumption can regulate the growth of tumors, a new perspective on the Warburg effect. PLoS ONE 4:e7033CrossRefPubMed Chen Y, Cairns R, Papandreou I, Koong A, Denko NC (2009) Oxygen consumption can regulate the growth of tumors, a new perspective on the Warburg effect. PLoS ONE 4:e7033CrossRefPubMed
65.
go back to reference Kimura K, Iwano M, Higgins DF, Yamaguchi Y, Nakatani K, Harada K, Kubo A, Akai Y, Rankin EB, Neilson EG, Haase VH, Saito Y (2008) Stable expression of HIF-1alpha in tubular epithelial cells promotes interstitial fibrosis. Am J Physiol Ren Physiol 295:F1023–1029CrossRef Kimura K, Iwano M, Higgins DF, Yamaguchi Y, Nakatani K, Harada K, Kubo A, Akai Y, Rankin EB, Neilson EG, Haase VH, Saito Y (2008) Stable expression of HIF-1alpha in tubular epithelial cells promotes interstitial fibrosis. Am J Physiol Ren Physiol 295:F1023–1029CrossRef
66.
go back to reference Otrock ZK, Hatoum HA, Awada AH, Ishak RS, Shamseddine AI (2009) Hypoxia-inducible factor in cancer angiogenesis: structure, regulation and clinical perspectives. Crit Rev Oncol Hematol 70:93–102CrossRefPubMed Otrock ZK, Hatoum HA, Awada AH, Ishak RS, Shamseddine AI (2009) Hypoxia-inducible factor in cancer angiogenesis: structure, regulation and clinical perspectives. Crit Rev Oncol Hematol 70:93–102CrossRefPubMed
67.
go back to reference Maxwell PH (2002) Oxygen homeostasis and cancer: insights from a rare disease. Clin Med 2:356–362PubMed Maxwell PH (2002) Oxygen homeostasis and cancer: insights from a rare disease. Clin Med 2:356–362PubMed
68.
go back to reference Loges S, Roncal C, Carmeliet P (2009) Development of targeted angiogenic medicine. J Thromb Haemost 7:21–33CrossRefPubMed Loges S, Roncal C, Carmeliet P (2009) Development of targeted angiogenic medicine. J Thromb Haemost 7:21–33CrossRefPubMed
69.
go back to reference Sasabe E, Zhou X, Li D, Oku N, Yamamoto T, Osaki T (2007) The involvement of hypoxia-inducible factor-1alpha in the susceptibility to gamma-rays and chemotherapeutic drugs of oral squamous cell carcinoma cells. Int J Cancer 120:277CrossRef Sasabe E, Zhou X, Li D, Oku N, Yamamoto T, Osaki T (2007) The involvement of hypoxia-inducible factor-1alpha in the susceptibility to gamma-rays and chemotherapeutic drugs of oral squamous cell carcinoma cells. Int J Cancer 120:277CrossRef
70.
go back to reference Bedogni B, Welford SM, Cassarino DS, Nickoloff BJ, Giaccia AJ, Powell MB (2005) The hypoxic microenvironment of the skin contributes to Akt-mediated melanocyte transformation. Cancer Cell 8:443–454CrossRefPubMed Bedogni B, Welford SM, Cassarino DS, Nickoloff BJ, Giaccia AJ, Powell MB (2005) The hypoxic microenvironment of the skin contributes to Akt-mediated melanocyte transformation. Cancer Cell 8:443–454CrossRefPubMed
71.
go back to reference Bedogni B, O’Neill MS, Welford SM, Bouley DM, Giaccia AJ, Denko NC, Powell MB (2004) Topical treatment with inhibitors of the phosphatidylinositol 3′-kinase/Akt and Raf/mitogen-activated protein kinase kinase/extracellular signal-regulated kinase pathways reduces melanoma development in severe combined immunodeficient mice. Cancer Res 64:2552–2560CrossRefPubMed Bedogni B, O’Neill MS, Welford SM, Bouley DM, Giaccia AJ, Denko NC, Powell MB (2004) Topical treatment with inhibitors of the phosphatidylinositol 3′-kinase/Akt and Raf/mitogen-activated protein kinase kinase/extracellular signal-regulated kinase pathways reduces melanoma development in severe combined immunodeficient mice. Cancer Res 64:2552–2560CrossRefPubMed
72.
go back to reference McCarty MF, Barroso-Aranda J, Contreras F (2010) Practical strategies for suppressing hypoxia-inducible factor activity in cancer therapy. Med Hypotheses 74:789–797CrossRefPubMed McCarty MF, Barroso-Aranda J, Contreras F (2010) Practical strategies for suppressing hypoxia-inducible factor activity in cancer therapy. Med Hypotheses 74:789–797CrossRefPubMed
73.
go back to reference Henk JM, Bishop K, Shepherd SF (2003) Treatment of head and neck cancer with CHART and nimorazole: phase II study. Radiother Oncol 66:65–70CrossRefPubMed Henk JM, Bishop K, Shepherd SF (2003) Treatment of head and neck cancer with CHART and nimorazole: phase II study. Radiother Oncol 66:65–70CrossRefPubMed
74.
go back to reference Reddy SB, Williamson SK (2009) Tirapazamine: a novel agent targeting hypoxic tumor cells. Expert Opin Investig Drugs 18:77–87CrossRefPubMed Reddy SB, Williamson SK (2009) Tirapazamine: a novel agent targeting hypoxic tumor cells. Expert Opin Investig Drugs 18:77–87CrossRefPubMed
75.
go back to reference Albertella MR, Loadman PM, Jones PH, Phillips RM, Rampling R, Burnet N, Alcock C, Anthoney A, Vjaters E, Dunk CR, Harris PA, Wong A, Lalani AS, Twelves CJ (2008) Hypoxia-selective targeting by the bioreductive prodrug AQ4N in patients with solid tumors: results of a phase I study. Clin Cancer Res 14:1096–1104CrossRefPubMed Albertella MR, Loadman PM, Jones PH, Phillips RM, Rampling R, Burnet N, Alcock C, Anthoney A, Vjaters E, Dunk CR, Harris PA, Wong A, Lalani AS, Twelves CJ (2008) Hypoxia-selective targeting by the bioreductive prodrug AQ4N in patients with solid tumors: results of a phase I study. Clin Cancer Res 14:1096–1104CrossRefPubMed
76.
go back to reference Sitkovsky MV (2009) T regulatory cells: hypoxia-adenosinergic suppression and re-direction of the immune response. Trends Immunol 30:102–108CrossRefPubMed Sitkovsky MV (2009) T regulatory cells: hypoxia-adenosinergic suppression and re-direction of the immune response. Trends Immunol 30:102–108CrossRefPubMed
77.
go back to reference Sitkovsky MV, Kjaergaard J, Lukashev D, Ohta A (2008) Hypoxia-adenosinergic immunosuppression: tumor protection by T regulatory cells and cancerous tissue hypoxia. Clin Cancer Res 14:5947–5952CrossRefPubMed Sitkovsky MV, Kjaergaard J, Lukashev D, Ohta A (2008) Hypoxia-adenosinergic immunosuppression: tumor protection by T regulatory cells and cancerous tissue hypoxia. Clin Cancer Res 14:5947–5952CrossRefPubMed
78.
go back to reference Chen L, Waxman DJ (2002) Cytochrome P450 gene-directed enzyme prodrug therapy (GDEPT) for cancer. Curr Pharm Des 8:1405–1416CrossRefPubMed Chen L, Waxman DJ (2002) Cytochrome P450 gene-directed enzyme prodrug therapy (GDEPT) for cancer. Curr Pharm Des 8:1405–1416CrossRefPubMed
79.
go back to reference McDonough MA, McNeill LA, Tilliet M, Papamicael CA, Chen QY, Banerji B, Hewitson KS, Schofield CJ (2005) Selective inhibition of factor inhibiting hypoxia-inducible factor. J Am Chem Soc 127:7680–7681CrossRefPubMed McDonough MA, McNeill LA, Tilliet M, Papamicael CA, Chen QY, Banerji B, Hewitson KS, Schofield CJ (2005) Selective inhibition of factor inhibiting hypoxia-inducible factor. J Am Chem Soc 127:7680–7681CrossRefPubMed
80.
go back to reference Asikainen TM, Ahmad A, Schneider BK, Ho WB, Arend M, Brenner M, Gunzler V, White CW (2005) Stimulation of HIF-1alpha, HIF-2alpha, and VEGF by prolyl 4-hydroxylase inhibition in human lung endothelial and epithelial cells. Free Radic Biol Med 38:1002–1013CrossRefPubMed Asikainen TM, Ahmad A, Schneider BK, Ho WB, Arend M, Brenner M, Gunzler V, White CW (2005) Stimulation of HIF-1alpha, HIF-2alpha, and VEGF by prolyl 4-hydroxylase inhibition in human lung endothelial and epithelial cells. Free Radic Biol Med 38:1002–1013CrossRefPubMed
81.
go back to reference Zaman K, Ryu H, Hall D, O’Donovan K, Lin KI, Miller MP, Marquis JC, Baraban JM, Semenza GL, Ratan RR (1999) Protection from oxidative stress-induced apoptosis in cortical neuronal cultures by iron chelators is associated with enhanced DNA binding of hypoxia-inducible factor-1 and ATF-1/CREB and increased expression of glycolytic enzymes, p21(waf1/cip1), and erythropoietin. J Neurosci 19:9821–9830PubMed Zaman K, Ryu H, Hall D, O’Donovan K, Lin KI, Miller MP, Marquis JC, Baraban JM, Semenza GL, Ratan RR (1999) Protection from oxidative stress-induced apoptosis in cortical neuronal cultures by iron chelators is associated with enhanced DNA binding of hypoxia-inducible factor-1 and ATF-1/CREB and increased expression of glycolytic enzymes, p21(waf1/cip1), and erythropoietin. J Neurosci 19:9821–9830PubMed
82.
go back to reference Siddiq A, Ayoub IA, Chavez JC, Aminova L, Shah S, LaManna JC, Patton SM, Connor JR, Cherny RA, Volitakis I, Bush AI, Langsetmo I, Seeley T, Gunzler V, Ratan RR (2005) Hypoxia-inducible factor prolyl 4-hydroxylase inhibition. A target for neuroprotection in the central nervous system. J Biol Chem 280:41732–41743CrossRefPubMed Siddiq A, Ayoub IA, Chavez JC, Aminova L, Shah S, LaManna JC, Patton SM, Connor JR, Cherny RA, Volitakis I, Bush AI, Langsetmo I, Seeley T, Gunzler V, Ratan RR (2005) Hypoxia-inducible factor prolyl 4-hydroxylase inhibition. A target for neuroprotection in the central nervous system. J Biol Chem 280:41732–41743CrossRefPubMed
83.
go back to reference Raff H, Tzankoff SP, Fitzgerald RS (1982) Chemoreceptor involvement in cortisol responses to hypoxia in ventilated dogs. J Appl Physiol 52:1092–1096PubMed Raff H, Tzankoff SP, Fitzgerald RS (1982) Chemoreceptor involvement in cortisol responses to hypoxia in ventilated dogs. J Appl Physiol 52:1092–1096PubMed
84.
go back to reference Raff H, Shinsako J, Dallman MF (1984) Renin and ACTH responses to hypercapnia and hypoxia after chronic carotid chemodenervation. Am J Physiol 247:R412–417PubMed Raff H, Shinsako J, Dallman MF (1984) Renin and ACTH responses to hypercapnia and hypoxia after chronic carotid chemodenervation. Am J Physiol 247:R412–417PubMed
85.
go back to reference Zinkernagel AS, Johnson RS, Nizet V (2007) Hypoxia inducible factor (HIF) function in innate immunity and infection. J Mol Med 85:1339–1346CrossRefPubMed Zinkernagel AS, Johnson RS, Nizet V (2007) Hypoxia inducible factor (HIF) function in innate immunity and infection. J Mol Med 85:1339–1346CrossRefPubMed
86.
go back to reference Semenza GL, Prabhakar NR (2007) HIF-1-dependent respiratory, cardiovascular, and redox responses to chronic intermittent hypoxia. Antioxid Redox Signal 9:1391–1396CrossRefPubMed Semenza GL, Prabhakar NR (2007) HIF-1-dependent respiratory, cardiovascular, and redox responses to chronic intermittent hypoxia. Antioxid Redox Signal 9:1391–1396CrossRefPubMed
87.
go back to reference Fraisl P, Aragones J, Carmeliet P (2009) Inhibition of oxygen sensors as a therapeutic strategy for ischaemic and inflammatory disease. Nat Rev Drug Discov 8:139–152CrossRefPubMed Fraisl P, Aragones J, Carmeliet P (2009) Inhibition of oxygen sensors as a therapeutic strategy for ischaemic and inflammatory disease. Nat Rev Drug Discov 8:139–152CrossRefPubMed
88.
go back to reference Myllyharju J (2008) Prolyl 4-hydroxylases, key enzymes in the synthesis of collagens and regulation of the response to hypoxia, and their roles as treatment targets. Ann Med 40:402–417CrossRefPubMed Myllyharju J (2008) Prolyl 4-hydroxylases, key enzymes in the synthesis of collagens and regulation of the response to hypoxia, and their roles as treatment targets. Ann Med 40:402–417CrossRefPubMed
Metadata
Title
Hypoxia—implications for pharmaceutical developments
Authors
Lucas Donovan
Scott M. Welford
John Haaga
Joseph LaManna
Kingman P. Strohl
Publication date
01-12-2010
Publisher
Springer-Verlag
Published in
Sleep and Breathing / Issue 4/2010
Print ISSN: 1520-9512
Electronic ISSN: 1522-1709
DOI
https://doi.org/10.1007/s11325-010-0368-x

Other articles of this Issue 4/2010

Sleep and Breathing 4/2010 Go to the issue

Letter to the Editors

Yawning and thermoregulation

Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine